1779-LB: Hospitalization for Hypoglycemia and Its Risk Factors among Patients with Diabetes and Cognitive Impairment

Introduction: Hypoglycemia is the most common serious adverse effect of diabetes treatments and a major cause of hospitalization, with an increased risk in the presence of cognitive impairment. This study aimed to identify risk factors associated with hospitalization for hypoglycemia in patients with diabetes and cognitive impairment. Methods: Using 2012-2020 electronic health records data from University of Florida Health, we included patients with diabetes and cognitive impairment aged ≥50 years. The outcome was the first occurrence of hospitalization for hypoglycemia. Baseline variables include demographics, comorbidities, and comedications. Multivariate logistic regression was employed to calculate the adjusted odds ratio (AOR) and 95% confidence interval (CI) of hospitalization for hypoglycemia associated with baseline risk factors. Results: This study included 3,263 patients diagnosed with both diabetes and cognitive impairment, with a mean age of 71.8 years. Female and non-Hispanic Black population accounted for 55.8% and 36.1%, respectively. In a median follow-up period of 1.95 years (Interquartile range, 0.97-3.55), 12.6% (410 patients) experienced hospitalization for hypoglycemia. Compared with those with HbA1c of 7-7.9%, the AOR of hospitalization for hypoglycemia was 0.64 (95% CI 0.34-1.19), 0.89 (0.52-1.52), 2.19 (1.20-3.98), and 2.26 (1.24-4.10) among those with HbA1c 6, 6-6.9, 8-8.9, and ≥9%, respectively, in the multivariable logistic regression model. Additionally, prior hypoglycemia (AOR, 5.58, 95%CI, 2.67-11.67), chronic kidney disease (1.65; 1.08-2.53), and insulin use (2.25; 1.37-3.70) were independent risk factors for hospitalization for hypoglycemia. Conclusion: We identified several risk factors associated with hospitalization for hypoglycemia among patients with diabetes and cognitive impairment, offering insights into the identification of high-risk patients and potential preventive strategies. Disclosure H. Tang: None. Y. Lu: None. W.T. Donahoo: None. S.T. DeKosky: Advisory Panel; Acumen Pharmaceuticals, Cognition Therapeutics. Consultant; Eisai Inc., Novo Nordisk. Other Relationship; Prevail Pharmaceuticals, Vaccinex. Consultant; Biogen. Advisory Panel; Otsuka America Pharmaceutical, Inc. J. Bian: None. J. Guo: None.